<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC4539848/results/search/disease/results.xml">
  <result pre="Antiviral Drugs on Liver Function and Fibrosis in Patients With" exact="Hepatitis" post="B: A Meta-Analysis LongLi-Hui1*XueCai-Qin1ShiJun-Feng1DongJuan-Ni1WangLi2[1], [2], *Corresponding Author: Li-Hui Long,"/>
  <result pre="combination with other antiviral or non-antiviral drugs in patients with" exact="hepatitis" post="B and hepatic fibrosis. Objectives: The current randomized controlled"/>
  <result pre="antiviral or non-antiviral drugs in patients with hepatitis B and" exact="hepatic fibrosis." post="Objectives: The current randomized controlled clinical trials aimed to"/>
  <result pre="of combinations of antiviral and non-antiviral hepatoprotective agents on indexes" exact="of liver" post="function and liver fibrosis in patients with hepatitis B."/>
  <result pre="and non-antiviral hepatoprotective agents on indexes of liver function and" exact="liver fibrosis" post="in patients with hepatitis B. Data Sources: Published literatures"/>
  <result pre="indexes of liver function and liver fibrosis in patients with" exact="hepatitis" post="B. Data Sources: Published literatures in Chinese and English"/>
  <result pre="literatures in Chinese and English on hepatoprotective treatment strategies for" exact="chronic hepatitis" post="B and liver fibrosis were searched in three databases"/>
  <result pre="in Chinese and English on hepatoprotective treatment strategies for chronic" exact="hepatitis" post="B and liver fibrosis were searched in three databases"/>
  <result pre="English on hepatoprotective treatment strategies for chronic hepatitis B and" exact="liver fibrosis" post="were searched in three databases and randomized controlled clinical"/>
  <result pre="criteria. Meta-analysis was employed to analyze the data. Results: A" exact="total" post="of 22 randomized controlled trials encompassing 1,714 cases were"/>
  <result pre="than antiviral drug alone to improve liver function. Similarly, regarding" exact="liver fibrosis," post="using two different hepatoprotective agents was better than using"/>
  <result pre="using one agent. The normalization rates of Aminotransferase (ALT) and" exact="total" post="Bilirubin (TBil) were improved 25.7% by two hepatoprotective agents"/>
  <result pre="combined with antiviral drugs can significantly improve liver function and" exact="liver fibrosis" post="parameters in patients with hepatitis B. Hepatitis B Liver"/>
  <result pre="improve liver function and liver fibrosis parameters in patients with" exact="hepatitis" post="B. Hepatitis B Liver Cirrhosis Meta-Analysis Ursodeoxycholic Acid (UDCA)"/>
  <result pre="function and liver fibrosis parameters in patients with hepatitis B." exact="Hepatitis" post="B Liver Cirrhosis Meta-Analysis Ursodeoxycholic Acid (UDCA) Silibinin Acetylcysteine"/>
  <result pre="Meta-Analysis Ursodeoxycholic Acid (UDCA) Silibinin Acetylcysteine 1. Context At present," exact="Hepatitis" post="B Virus (HBV) infection is an important public health"/>
  <result pre="Silibinin Acetylcysteine 1. Context At present, Hepatitis B Virus (HBV)" exact="infection" post="is an important public health problem worldwide. Hepatitis B"/>
  <result pre="Virus (HBV) infection is an important public health problem worldwide." exact="Hepatitis" post="B can lead to serious liver diseases, including cirrhosis,"/>
  <result pre="Hepatitis B can lead to serious liver diseases, including cirrhosis," exact="liver cancer." post="In China, approximately 120 million people are infected with"/>
  <result pre="In China, approximately 120 million people are infected with the" exact="Hepatitis" post="B Virus (1). Alavian et al. reported that about"/>
  <result pre="in Iran, and 15% to 40% of the patients with" exact="hepatitis" post="B may develop cirrhosis or liver cancer (2). Liver"/>
  <result pre="to 40% of the patients with hepatitis B may develop" exact="cirrhosis" post="or liver cancer (2). Liver fibrosis is a healing"/>
  <result pre="of the patients with hepatitis B may develop cirrhosis or" exact="liver cancer" post="(2). Liver fibrosis is a healing response, but the"/>
  <result pre="the patients with hepatitis B may develop cirrhosis or liver" exact="cancer" post="(2). Liver fibrosis is a healing response, but the"/>
  <result pre="(ECM) components in the liver often leads to severe forms" exact="of liver" post="fibrosis, and ultimately cirrhosis with liver dysfunction (3-5). Early"/>
  <result pre="components in the liver often leads to severe forms of" exact="liver fibrosis," post="and ultimately cirrhosis with liver dysfunction (3-5). Early cirrhosis"/>
  <result pre="often leads to severe forms of liver fibrosis, and ultimately" exact="cirrhosis" post="with liver dysfunction (3-5). Early cirrhosis may be reversible."/>
  <result pre="liver fibrosis, and ultimately cirrhosis with liver dysfunction (3-5). Early" exact="cirrhosis" post="may be reversible. Therefore, prompt diagnosis and intervention are"/>
  <result pre="reversible. Therefore, prompt diagnosis and intervention are critical in limiting" exact="disease" post="progression (6). Clinically, the existing hepatoprotective agents include Ursodesoxycholic"/>
  <result pre="acid, and improves cholestasis. UDCA is mainly used to treat" exact="primary biliary cirrhosis," post="hepatitis B associated liver fibrosis, and cholestatic liver disease,"/>
  <result pre="cholestasis. UDCA is mainly used to treat primary biliary cirrhosis," exact="hepatitis" post="B associated liver fibrosis, and cholestatic liver disease, the"/>
  <result pre="mainly used to treat primary biliary cirrhosis, hepatitis B associated" exact="liver fibrosis," post="and cholestatic liver disease, the efficacy is certain. Some"/>
  <result pre="primary biliary cirrhosis, hepatitis B associated liver fibrosis, and cholestatic" exact="liver disease," post="the efficacy is certain. Some studies reported that UDCA"/>
  <result pre="ursodeoxycholic acid to regulate cell cycle, apoptosis and protein biosynthesis" exact="of liver" post="cells. Alternatively, the increased pool of hydrophilic bile acid"/>
  <result pre="role (7, 8). UDCA, which causes minimal damage and is" exact="non-toxic" post="to liver cells, is an effective hepatoprotective agent and"/>
  <result pre="showed that ursodeoxycholic acid can significantly reduce the development of" exact="hepatic fibrosis" post="(8, 10, 11). Silibinin is derived from milk thistle,"/>
  <result pre="the United States and Europe, about 65% of patients with" exact="liver disease" post="use Chinese medical preparations which include milk thistle as"/>
  <result pre="United States and Europe, about 65% of patients with liver" exact="disease" post="use Chinese medical preparations which include milk thistle as"/>
  <result pre="(14). In recent years, silibinin has been used to treat" exact="liver cirrhosis," post="hepatitis, liver fibrosis and alcoholic liver disease (15). N-acetylcysteine"/>
  <result pre="years, silibinin has been used to treat liver cirrhosis, hepatitis," exact="liver fibrosis" post="and alcoholic liver disease (15). N-acetylcysteine (NAC) is an"/>
  <result pre="been used to treat liver cirrhosis, hepatitis, liver fibrosis and" exact="alcoholic" post="liver disease (15). N-acetylcysteine (NAC) is an intracellular glutathione"/>
  <result pre="used to treat liver cirrhosis, hepatitis, liver fibrosis and alcoholic" exact="liver disease" post="(15). N-acetylcysteine (NAC) is an intracellular glutathione precursor, which"/>
  <result pre="to treat liver cirrhosis, hepatitis, liver fibrosis and alcoholic liver" exact="disease" post="(15). N-acetylcysteine (NAC) is an intracellular glutathione precursor, which"/>
  <result pre="have demonstrated that NAC is not only effective to treat" exact="liver failure" post="caused by excessive acetaminophen (paracetamol), but is also useful"/>
  <result pre="caused by excessive acetaminophen (paracetamol), but is also useful for" exact="liver disease" post="arising from other causes (18). NAC reduces serum Total"/>
  <result pre="by excessive acetaminophen (paracetamol), but is also useful for liver" exact="disease" post="arising from other causes (18). NAC reduces serum Total"/>
  <result pre="liver disease arising from other causes (18). NAC reduces serum" exact="Total" post="Bilirubin (TBil) and aminotransferases, and increases Prothrombin activity (PTA)"/>
  <result pre="aminotransferases, and increases Prothrombin activity (PTA) in patients with severe" exact="chronic hepatitis" post="B (19). 2. Objectives The current study aimed to"/>
  <result pre="and increases Prothrombin activity (PTA) in patients with severe chronic" exact="hepatitis" post="B (19). 2. Objectives The current study aimed to"/>
  <result pre="of antiviral and non-antiviral hepatoprotective agents combinations on the indexes" exact="of liver" post="function and liver fibrosis in patients with hepatitis B."/>
  <result pre="hepatoprotective agents combinations on the indexes of liver function and" exact="liver fibrosis" post="in patients with hepatitis B. 3. Data Sources Papers"/>
  <result pre="indexes of liver function and liver fibrosis in patients with" exact="hepatitis" post="B. 3. Data Sources Papers written in either English"/>
  <result pre="or Chinese describing the use of hepatoprotective agents to treat" exact="hepatitis" post="and liver fibrosis were retrieved. Using &quot;chronic hepatitis B,"/>
  <result pre="describing the use of hepatoprotective agents to treat hepatitis and" exact="liver fibrosis" post="were retrieved. Using &quot;chronic hepatitis B, hepatitis B, HBV,"/>
  <result pre="to treat hepatitis and liver fibrosis were retrieved. Using &quot;chronic" exact="hepatitis" post="B, hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin,"/>
  <result pre="hepatitis and liver fibrosis were retrieved. Using &quot;chronic hepatitis B," exact="hepatitis" post="B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine),"/>
  <result pre="fibrosis were retrieved. Using &quot;chronic hepatitis B, hepatitis B, HBV," exact="liver fibrosis," post="hepatoprotective, silibinin (silymarin, silybin meglumine), acetylcysteine and ursodeoxycholic bile"/>
  <result pre="Study Selection 4.1. Inclusion and Exclusion Criteria 4.1.1. Inclusion Criteria" exact="Hepatitis" post="B infection or liver fibrosis; chronic hepatitis B was"/>
  <result pre="4.1. Inclusion and Exclusion Criteria 4.1.1. Inclusion Criteria Hepatitis B" exact="infection" post="or liver fibrosis; chronic hepatitis B was diagnosed if"/>
  <result pre="and Exclusion Criteria 4.1.1. Inclusion Criteria Hepatitis B infection or" exact="liver fibrosis;" post="chronic hepatitis B was diagnosed if HBV history or"/>
  <result pre="Criteria 4.1.1. Inclusion Criteria Hepatitis B infection or liver fibrosis;" exact="chronic hepatitis" post="B was diagnosed if HBV history or HBV markers"/>
  <result pre="4.1.1. Inclusion Criteria Hepatitis B infection or liver fibrosis; chronic" exact="hepatitis" post="B was diagnosed if HBV history or HBV markers"/>
  <result pre="months and serum alanine aminotransferase levels exceeded 80 IU/L, and" exact="hepatic fibrosis" post="was estimated by indexes containing the following markers: HA,"/>
  <result pre="(γ-GGT), Alkaline Phosphatase (ALP), Hyaluronic acid (HA), Laminin (LN), Collagen" exact="type IV" post="(CIV), and Procollagen III peptide (PIIIP). Trials were limited"/>
  <result pre="type IV (CIV), and Procollagen III peptide (PIIIP). Trials were" exact="limited" post="to those comparing the efficacy of different drugs or"/>
  <result pre="Studies in which non-protective liver drugs were used to treat" exact="viral hepatitis" post="or liver fibrosis; animal experiments and reviewed papers that"/>
  <result pre="in which non-protective liver drugs were used to treat viral" exact="hepatitis" post="or liver fibrosis; animal experiments and reviewed papers that"/>
  <result pre="non-protective liver drugs were used to treat viral hepatitis or" exact="liver fibrosis;" post="animal experiments and reviewed papers that did not contain"/>
  <result pre="papers that did not contain clinical data; pregnant and lactating" exact="female" post="patients with liver disease. The therapy course was less"/>
  <result pre="not contain clinical data; pregnant and lactating female patients with" exact="liver disease." post="The therapy course was less than three weeks; liver"/>
  <result pre="levels of ALT, AST, GGT, TBIL and other basic indicators" exact="of liver" post="function were restored to within the normal range. 2)"/>
  <result pre="ALT (U/L), GGT (U/L), ALP (U/L) and TBIL (U/L); (2)" exact="liver fibrosis" post="markers: HA (μg/L), LN (μg/L), IV-C (μg/L) and PIIIP"/>
  <result pre="Finally, 22 standard randomized controlled trials were included, with a" exact="total" post="of 1,756 subjects, among whom 893 subjects were in"/>
  <result pre="auxin 0.1 g/d + plasma 200 ml qod + other" exact="symptomatic" post="and supportive treatments) 30 d TBIL Shi et al."/>
  <result pre="g qod + ranitidine 150 mg po tid + other" exact="symptomatic" post="and supportive treatments) 45 d ALT, AST, TBIL Wang"/>
  <result pre="g qod + ranitidine 150 mg po tid + other" exact="symptomatic" post="and supportive treatments) 45 d ALT, AST, TBIL Wang"/>
  <result pre="phosphatase Phosphatase; AST, aspartate Aspartate aminotransferase Aminotransferase; CIV collagen Collagen" exact="type IV;" post="HA, hyaluronic Hyaluronic acid Acid; LN, laminin Laminin; PIIIP,"/>
  <result pre="LN, laminin Laminin; PIIIP, procollagen Procollagen III peptide Peptide; TBIL," exact="total" post="bilirubin; γ-GGT, gamma-glutamyl Glutamyl transpeptidase Transpeptidase 6.2. Treatment Type"/>
  <result pre="IV-C and PIIIP (Table 1; figures 6 and 7) as" exact="hepatic fibrosis" post="markers. 6.3. Hepatoprotective Drug Combined With Antiviral Drug vs."/>
  <result pre="6 and 7) as hepatic fibrosis markers. 6.3. Hepatoprotective Drug" exact="Combined" post="With Antiviral Drug vs. Antiviral Drug Alone Six randomized"/>
  <result pre="hepatoprotective drug in combination with an antiviral agent treatment of" exact="chronic hepatitis" post="B. The test and control groups included 741 and"/>
  <result pre="drug in combination with an antiviral agent treatment of chronic" exact="hepatitis" post="B. The test and control groups included 741 and"/>
  <result pre="on ALT, AST, ALP and TBIL Levels In patients with" exact="chronic hepatitis" post="B infection treated with combination hepatoprotective and antiviral drug"/>
  <result pre="ALT, AST, ALP and TBIL Levels In patients with chronic" exact="hepatitis" post="B infection treated with combination hepatoprotective and antiviral drug"/>
  <result pre="ALP and TBIL Levels In patients with chronic hepatitis B" exact="infection" post="treated with combination hepatoprotective and antiviral drug vs. antiviral"/>
  <result pre="compared with placebo on liver function indexes in patients with" exact="chronic hepatitis" post="B, including ALT and TBIL. In these trials, the"/>
  <result pre="with placebo on liver function indexes in patients with chronic" exact="hepatitis" post="B, including ALT and TBIL. In these trials, the"/>
  <result pre="three hepatoprotective agents significantly decreased ALT levels in patients with" exact="hepatitis" post="B. NAC was associated with greater efficacy compared to"/>
  <result pre="of UDCA and silibinin on ALT levels in patients with" exact="hepatitis" post="B were considerable: NAC (WMD = -25.66; P ="/>
  <result pre="[-49.52, 4.72]) (Figure 2). Figure 2. Meta-Analysis Forest Plots Indicating" exact="Reduced" post="Amounts of ALT In patients with chronic hepatitis B"/>
  <result pre="Forest Plots Indicating Reduced Amounts of ALT In patients with" exact="chronic hepatitis" post="B infection treated with hepatoprotective drugs vs. placebo. Data"/>
  <result pre="Plots Indicating Reduced Amounts of ALT In patients with chronic" exact="hepatitis" post="B infection treated with hepatoprotective drugs vs. placebo. Data"/>
  <result pre="Reduced Amounts of ALT In patients with chronic hepatitis B" exact="infection" post="treated with hepatoprotective drugs vs. placebo. Data are presented"/>
  <result pre="over NAC and silibinin to reduce TBIL in patients with" exact="hepatitis" post="B. Meta-analysis showed that NAC (WMD = -2.56; P"/>
  <result pre="Hepatoprotective Agents vs. Placebo on TBIL Levels In patients with" exact="chronic hepatitis" post="B infection. Data are presented as pooled relative risks"/>
  <result pre="Agents vs. Placebo on TBIL Levels In patients with chronic" exact="hepatitis" post="B infection. Data are presented as pooled relative risks"/>
  <result pre="hepatoprotective agents compared to only one to treat patients with" exact="chronic hepatitis" post="B. There were 618 subjects in the two hepatoprotective"/>
  <result pre="agents compared to only one to treat patients with chronic" exact="hepatitis" post="B. There were 618 subjects in the two hepatoprotective"/>
  <result pre="ALT, AST, GGT, ALP and TBIL levels in patients with" exact="hepatitis" post="B. ALT (WMD=-31.44; 95% CI [-48.57,-14.32]), AST (WMD ="/>
  <result pre="Figure 4. Meta-Analysis Forest Plots for Effects In patients with" exact="chronic hepatitis" post="B infection treated with the combination of two liver"/>
  <result pre="4. Meta-Analysis Forest Plots for Effects In patients with chronic" exact="hepatitis" post="B infection treated with the combination of two liver"/>
  <result pre="Forest Plots for Effects In patients with chronic hepatitis B" exact="infection" post="treated with the combination of two liver protective drugs"/>
  <result pre="Hepatoprotective Agent on Recovery of Liver Function in Patients With" exact="Hepatitis" post="B Three randomized controlled clinical trials reported the effects"/>
  <result pre="drugs compared to a single agent on the recovery rate" exact="of liver" post="indicators in patients with hepatitis B; 173 subjects who"/>
  <result pre="on the recovery rate of liver indicators in patients with" exact="hepatitis" post="B; 173 subjects who used a combination of two"/>
  <result pre="the Normalization Rates of ALT and TBIL In patients with" exact="chronic hepatitis" post="B infection treated with two vs. one hepatoprotective agent."/>
  <result pre="Normalization Rates of ALT and TBIL In patients with chronic" exact="hepatitis" post="B infection treated with two vs. one hepatoprotective agent."/>
  <result pre="of ALT and TBIL In patients with chronic hepatitis B" exact="infection" post="treated with two vs. one hepatoprotective agent. Data are"/>
  <result pre="of Hepatoprotective Agents on Liver Fibrosis Indexes in Patients With" exact="Hepatitis" post="B Three randomized controlled clinical trials reported the effects"/>
  <result pre="controlled clinical trials reported the effects of hepatoprotective agents on" exact="liver fibrosis" post="markers, HA, IV-C and PIIIP. From the three studies,"/>
  <result pre="that hepatoprotective agents were indeed associated with improved indices of" exact="hepatic fibrosis" post="compared to placebo: HA (WMD = -55.65, 95% CI"/>
  <result pre="on Levels of HA, IV-C and PIIIP In patients with" exact="liver fibrosis." post="Data are presented as pooled mean difference using a"/>
  <result pre="of combined hepatoprotective agents versus a single agent on the" exact="liver fibrosis" post="index, LN. The group representing the combined hepatoprotective agents"/>
  <result pre="Forest Plots of LN Levels in Patients With Liver Fibrosis" exact="Infection" post="Treated with Two vs. one Hepatoprotective Agents Data are"/>
  <result pre="of ALT, AST and TBIL was conducted, in patients with" exact="hepatitis" post="B (Figure 8). The Funnel plot showed that the"/>
  <result pre="on normalization of ALT, AST and TBIL, in patients with" exact="hepatitis" post="B 7. Discussion The current model is expected to"/>
  <result pre="current model is expected to maximize long-term treatment of severe" exact="liver disease" post="caused by HBV infection to suppress the virus, improve"/>
  <result pre="model is expected to maximize long-term treatment of severe liver" exact="disease" post="caused by HBV infection to suppress the virus, improve"/>
  <result pre="maximize long-term treatment of severe liver disease caused by HBV" exact="infection" post="to suppress the virus, improve inflammation and necrosis, and"/>
  <result pre="damage, promote the liver cell membrane and promote the recovery" exact="of liver" post="function, and it may delay the formation and development"/>
  <result pre="function, and it may delay the formation and development of" exact="hepatic fibrosis" post="(38). Some studies showed a synergistic effect between hepatoprotective"/>
  <result pre="in drug tolerance due to hepatoprotective agents in patients with" exact="hepatitis" post="B (34, 40). In 2006, Qureshi et al reported"/>
  <result pre="doses of ursodeoxycholic acid reduces ALT levels in patients with" exact="hepatitis" post="B (28). The meta-analysis of the current study showed"/>
  <result pre="ALT, and were a liver function marker in patients with" exact="hepatitis" post="B. The reduction in ALT levels by acetylcysteine was"/>
  <result pre="of serum II-18, IFN-γ and NO in the patients with" exact="hepatitis" post="B. Some studies stated that acetylcysteine should be used,"/>
  <result pre="used, and that it was more beneficial in early stages" exact="of liver" post="disease (21). The limitations of the study included the"/>
  <result pre="and that it was more beneficial in early stages of" exact="liver disease" post="(21). The limitations of the study included the retrospective"/>
  <result pre="that it was more beneficial in early stages of liver" exact="disease" post="(21). The limitations of the study included the retrospective"/>
  <result pre="drugs can effectively improve serum liver markers in patients with" exact="liver fibrosis" post="when combined with antiviral or other hepatoprotective agents. The"/>
  <result pre="1LiangGNChenLHGlycyrrhizin injection combined with Danshen injection observe the effect of" exact="hepatitis" post="B liver fibrosis.J Tibetan Med.2010311245 2AlavianSMTabatabaeiSVGhadimiTBeedrapourFKafi-AbadSAGharehbaghianAet al.Seroprevalence of Hepatitis"/>
  <result pre="of hepatitis B liver fibrosis.J Tibetan Med.2010311245 2AlavianSMTabatabaeiSVGhadimiTBeedrapourFKafi-AbadSAGharehbaghianAet al.Seroprevalence of" exact="Hepatitis" post="B Virus Infection and Its Risk Factors in the"/>
  <result pre="liver fibrosis.J Tibetan Med.2010311245 2AlavianSMTabatabaeiSVGhadimiTBeedrapourFKafi-AbadSAGharehbaghianAet al.Seroprevalence of Hepatitis B Virus" exact="Infection" post="and Its Risk Factors in the West of Iran:"/>
  <result pre="FIB-4 and comparison with other simple noninvasive indices for predicting" exact="liver fibrosis" post="and cirrhosis in hepatitis B virus-infected patients.Liver Int.20103045465310.1111/j.1478-3231.2009.02192.x20074094 6LimYSKimWRThe"/>
  <result pre="with other simple noninvasive indices for predicting liver fibrosis and" exact="cirrhosis" post="in hepatitis B virus-infected patients.Liver Int.20103045465310.1111/j.1478-3231.2009.02192.x20074094 6LimYSKimWRThe global impact"/>
  <result pre="simple noninvasive indices for predicting liver fibrosis and cirrhosis in" exact="hepatitis" post="B virus-infected patients.Liver Int.20103045465310.1111/j.1478-3231.2009.02192.x20074094 6LimYSKimWRThe global impact of hepatic"/>
  <result pre="in hepatitis B virus-infected patients.Liver Int.20103045465310.1111/j.1478-3231.2009.02192.x20074094 6LimYSKimWRThe global impact of" exact="hepatic fibrosis" post="and end-stage liver disease.Clin Liver Dis.20081247334610.1016/j.cld.2008.07.00718984463 7CaoRHuXDChengHObservation on the"/>
  <result pre="of adenosine combine with ursodeoxycholic acid in the treatment of" exact="chronic hepatitis" post="B with severe jaundice.Chin Hosp Pharm J Dis.20033264813 8GaoYSongMZLiangCRClinical"/>
  <result pre="adenosine combine with ursodeoxycholic acid in the treatment of chronic" exact="hepatitis" post="B with severe jaundice.Chin Hosp Pharm J Dis.20033264813 8GaoYSongMZLiangCRClinical"/>
  <result pre="severe jaundice.Chin Hosp Pharm J Dis.20033264813 8GaoYSongMZLiangCRClinical Observation of Ademetionine" exact="Combined" post="With Ursodeoxycholic Acid in the Treatment ofChronic Severe Cholestatic"/>
  <result pre="of Ademetionine Combined With Ursodeoxycholic Acid in the Treatment ofChronic" exact="Severe" post="Cholestatic Hepatitis.Chin Hosp Pharm Dis.2013143689 9JooSSKangHCWonTJLeeDIUrsodeoxycholic acid inhibits pro-inflammatory"/>
  <result pre="of ursodeoxycholic acid in liver functional restoration of patients with" exact="obstructive jaundice" post="after endoscopic treatment: a prospective, randomized, and controlled study.BMC"/>
  <result pre="controlled study.BMC Surg.2013133810.1186/1471-2482-13-3824053627 11BobergKMWisloffTKjollesdalKSStovringHKristiansenISCost and health consequences of treatment of" exact="primary biliary cirrhosis" post="with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the treatment"/>
  <result pre="Surg.2013133810.1186/1471-2482-13-3824053627 11BobergKMWisloffTKjollesdalKSStovringHKristiansenISCost and health consequences of treatment of primary biliary" exact="cirrhosis" post="with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the treatment"/>
  <result pre="with ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the treatment of" exact="acute" post="viral hepatitis].Wiad Lek.198336861366353775 13WeiFLiuSKLiuXYLiZJLiBZhouYLet al.Meta-analysis: silymarin and its combination"/>
  <result pre="ursodeoxycholic acid.Aliment Pharmacol Ther.201338779480310.1111/apt.1243523915021 12TkaczBDworniakD[Sylimarol in the treatment of acute" exact="viral" post="hepatitis].Wiad Lek.198336861366353775 13WeiFLiuSKLiuXYLiZJLiBZhouYLet al.Meta-analysis: silymarin and its combination therapy"/>
  <result pre="al.Meta-analysis: silymarin and its combination therapy for the treatment of" exact="chronic hepatitis" post="B.Eur J Clin Microbiol Infect Dis.20133256576910.1007/s10096-012-1789-123247631 14RenBRZhaoYYXuBHWuJLChenJLiangCYResearch of silymarin"/>
  <result pre="silymarin and its combination therapy for the treatment of chronic" exact="hepatitis" post="B.Eur J Clin Microbiol Infect Dis.20133256576910.1007/s10096-012-1789-123247631 14RenBRZhaoYYXuBHWuJLChenJLiangCYResearch of silymarin"/>
  <result pre="purification.Lishizhen Med Materia Med Res.20122336556 15FeherJLengyelG[Silymarin in the treatment of" exact="chronic" post="liver diseases: past and future].Orv Hetil.2008149512413810.1556/OH.2008.2851919073452 16HofferEBaumYTabakATaitelmanUN-acetylcysteine increases the"/>
  <result pre="Hetil.2008149512413810.1556/OH.2008.2851919073452 16HofferEBaumYTabakATaitelmanUN-acetylcysteine increases the glutathione content and protects rat alveolar" exact="type II" post="cells against paraquat-induced cytotoxicity.Toxicol Letters.199684171210.1016/0378-4274(95)03446-3 17HarrisonPWendonJWilliamsREvidence of increased guanylate"/>
  <result pre="update.Curr Gastroenterol Rep.19991142910980926 19WangNShiXFGuoSHZhangDZRenH[A clinical study of N-acetylcysteine treatment in" exact="chronic hepatitis" post="B patients].Zhonghua Gan Zang Bing Za Zhi.2008167487918647523 20XiaGThe clinical"/>
  <result pre="Gastroenterol Rep.19991142910980926 19WangNShiXFGuoSHZhangDZRenH[A clinical study of N-acetylcysteine treatment in chronic" exact="hepatitis" post="B patients].Zhonghua Gan Zang Bing Za Zhi.2008167487918647523 20XiaGThe clinical"/>
  <result pre="clinical efficacy observation of acetylcysteine injection on 58 cases of" exact="chronic" post="severe hepatitis B.West Chin Med J.2009245123940 21ShiXFGuoSHWuGWangZYRenHLiuQThe clinical curative"/>
  <result pre="observation of acetylcysteine injection on 58 cases of chronic severe" exact="hepatitis" post="B.West Chin Med J.2009245123940 21ShiXFGuoSHWuGWangZYRenHLiuQThe clinical curative effect observation"/>
  <result pre="curative effect observation of acetylcysteine injection on 40 cases of" exact="chronic hepatitis" post="B.J Chongqing Med Univ.200530111521 22ShohratiMDermanakiFBabaeiFAlavianSMEvaluation of the effects of"/>
  <result pre="effect observation of acetylcysteine injection on 40 cases of chronic" exact="hepatitis" post="B.J Chongqing Med Univ.200530111521 22ShohratiMDermanakiFBabaeiFAlavianSMEvaluation of the effects of"/>
  <result pre="placebo in paraclinical and oxidative stress parameters of patients with" exact="chronic hepatitis" post="B.Hepat Mon.20101029510022312380 23WuGGuoSHThe Clinic Study of N-Acetylcysteine Injection Therapy"/>
  <result pre="in paraclinical and oxidative stress parameters of patients with chronic" exact="hepatitis" post="B.Hepat Mon.20101029510022312380 23WuGGuoSHThe Clinic Study of N-Acetylcysteine Injection Therapy"/>
  <result pre="B.Hepat Mon.20101029510022312380 23WuGGuoSHThe Clinic Study of N-Acetylcysteine Injection Therapy to" exact="Chronic" post="Hepatitis B.Chongqing Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on"/>
  <result pre="Mon.20101029510022312380 23WuGGuoSHThe Clinic Study of N-Acetylcysteine Injection Therapy to Chronic" exact="Hepatitis" post="B.Chongqing Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on liver"/>
  <result pre="Chronic Hepatitis B.Chongqing Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on" exact="liver cirrhosis" post="with hepatitis B].Zhong Nan Da Xue Xue Bao Yi"/>
  <result pre="Hepatitis B.Chongqing Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on liver" exact="cirrhosis" post="with hepatitis B].Zhong Nan Da Xue Xue Bao Yi"/>
  <result pre="Med Univer.200432549 24WangXShenSLiNLiY[Effect of Ursodeoxycholi acid on liver cirrhosis with" exact="hepatitis" post="B].Zhong Nan Da Xue Xue Bao Yi Xue Ban.2010352171510.3969/j.issn.1672-7347.2010.02.01420197618"/>
  <result pre="Ban.2010352171510.3969/j.issn.1672-7347.2010.02.01420197618 25FabrisPTosittiGMazzellaGZanettiARNicolinRPellizzerGet al.Effect of ursodeoxycholic acid administration in patients with" exact="acute" post="viral hepatitis: a pilot study.Aliment Pharmacol Ther.199913911879310468700 26AnguloPBattsKPTherneauTMJorgensenRADicksonERLindorKDLong-term ursodeoxycholic"/>
  <result pre="25FabrisPTosittiGMazzellaGZanettiARNicolinRPellizzerGet al.Effect of ursodeoxycholic acid administration in patients with acute" exact="viral" post="hepatitis: a pilot study.Aliment Pharmacol Ther.199913911879310468700 26AnguloPBattsKPTherneauTMJorgensenRADicksonERLindorKDLong-term ursodeoxycholic acid"/>
  <result pre="study.Aliment Pharmacol Ther.199913911879310468700 26AnguloPBattsKPTherneauTMJorgensenRADicksonERLindorKDLong-term ursodeoxycholic acid delays histological progression in" exact="primary" post="biliary cirrhosis.Hepatology.1999293644710.1002/hep.51029030110051462 27CAORHuXDCHENGHHUANGSBAITGANHet al.Observation on the clinical efficiency of"/>
  <result pre="adenosine methionine combined with ursodeoxycholic acid in the treatment of" exact="chronic hepatitis" post="B with severe jaundice.Chinese J Hos Pharm.20136019 28QureshiHMehdiIAhmedWUAlamSERole of"/>
  <result pre="methionine combined with ursodeoxycholic acid in the treatment of chronic" exact="hepatitis" post="B with severe jaundice.Chinese J Hos Pharm.20136019 28QureshiHMehdiIAhmedWUAlamSERole of"/>
  <result pre="Hos Pharm.20136019 28QureshiHMehdiIAhmedWUAlamSERole of ursodeoxycholic acid in lowering ALT in" exact="chronic" post="liver disease.J Pak Med Assoc.2006563130116696513 29RatziuVde LedinghenVObertiFMathurinPWartelle-BladouCRenouCet al.A randomized"/>
  <result pre="30FlisiakRProkopowiczDEffect of misoprostol on serum beta2-microglobulin in the course of" exact="viral hepatitis" post="B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the"/>
  <result pre="of misoprostol on serum beta2-microglobulin in the course of viral" exact="hepatitis" post="B.Eur J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the"/>
  <result pre="J Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the course of" exact="viral hepatitis" post="B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect of oxymatrine on specific cytotoxic T"/>
  <result pre="Gastroenterol Hepatol.1999111112273010563531 31FlisiakRProkopowiczDEffect of misoprostol on the course of viral" exact="hepatitis" post="B.Hepatogastroenterology.199744171419259356866 32GuXBYangXJHuaZLuZHZhangBZhuYFet al.Effect of oxymatrine on specific cytotoxic T"/>
  <result pre="T lymphocyte surface programmed death receptor-1 expression in patients with" exact="chronic hepatitis" post="B.Chin Med J (Engl).201212581434822613649 33BaoFYXieJSilybin phospholipid complex combinated with"/>
  <result pre="lymphocyte surface programmed death receptor-1 expression in patients with chronic" exact="hepatitis" post="B.Chin Med J (Engl).201212581434822613649 33BaoFYXieJSilybin phospholipid complex combinated with"/>
  <result pre="Med J (Engl).201212581434822613649 33BaoFYXieJSilybin phospholipid complex combinated with interferon treating" exact="hepatitis" post="B.J Cent Plains Med.20063315701 34BaoFYQiuPYAnalyzing the adjunctive therapy of"/>
  <result pre="Med.20063315701 34BaoFYQiuPYAnalyzing the adjunctive therapy of silibinin phospholipid complex treat" exact="chronic hepatitis" post="B in 86 cases.Shandong Med.2006262631 35KimMYChoMYBaikSKJeongPHSukKTJangYOet al.Beneficial effects of"/>
  <result pre="34BaoFYQiuPYAnalyzing the adjunctive therapy of silibinin phospholipid complex treat chronic" exact="hepatitis" post="B in 86 cases.Shandong Med.2006262631 35KimMYChoMYBaikSKJeongPHSukKTJangYOet al.Beneficial effects of"/>
  <result pre="35KimMYChoMYBaikSKJeongPHSukKTJangYOet al.Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated" exact="alcoholic" post="liver fibrosis - a randomized open-label controlled study.Liver Int.20123269778710.1111/j.1478-3231.2012.02774.x22364262"/>
  <result pre="al.Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic" exact="liver fibrosis" post="- a randomized open-label controlled study.Liver Int.20123269778710.1111/j.1478-3231.2012.02774.x22364262 36WangHZhaoYLXuKC[Clinical and"/>
  <result pre="pathological study on effects of Qianggan Capsule combined lamivudine on" exact="hepatic fibrosis" post="in patients with chronic hepatitis B].Zhongguo Zhong Xi Yi"/>
  <result pre="Qianggan Capsule combined lamivudine on hepatic fibrosis in patients with" exact="chronic hepatitis" post="B].Zhongguo Zhong Xi Yi Jie He Za Zhi.200626119788017186724 37WuYYaoDKZhuL[Clinical"/>
  <result pre="Capsule combined lamivudine on hepatic fibrosis in patients with chronic" exact="hepatitis" post="B].Zhongguo Zhong Xi Yi Jie He Za Zhi.200626119788017186724 37WuYYaoDKZhuL[Clinical"/>
  <result pre="ursodeoxycholic acid and fuzheng huayu capsule in the treatment of" exact="primary" post="biliary cirrhosis].Zhongguo Zhong Xi Yi Jie He Za Zhi.2012321114778223359968"/>
  <result pre="38MaoZYXiaoMWuXJTaoLGTanⅡA, Oxymatrine combined therapy on liver function in patients with" exact="chronic hepatitis" post="B and liver fibrosis.Pract Clin Med.2014152213 39ZhouXYGaoCGaoXCLiuXLLiLHWangXClinical effects of"/>
  <result pre="Oxymatrine combined therapy on liver function in patients with chronic" exact="hepatitis" post="B and liver fibrosis.Pract Clin Med.2014152213 39ZhouXYGaoCGaoXCLiuXLLiLHWangXClinical effects of"/>
  <result pre="and liver fibrosis.Pract Clin Med.2014152213 39ZhouXYGaoCGaoXCLiuXLLiLHWangXClinical effects of valsartan on" exact="liver fibrosis" post="indexes in patients with alcoholic liver cirrhosis.Chin J Integr"/>
  <result pre="effects of valsartan on liver fibrosis indexes in patients with" exact="alcoholic" post="liver cirrhosis.Chin J Integr Trad Western Med Live Dis.2014242856"/>
  <result pre="the effect of interferon α-2b combined with silymarin to treat" exact="chronic hepatitis" post="B.Clin Hepatol.20045302"/>
  <result pre="effect of interferon α-2b combined with silymarin to treat chronic" exact="hepatitis" post="B.Clin Hepatol.20045302"/>
 </snippets>
</snippetsTree>
